I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

There is no ideal protocol for postoperative pain management. Simple surgeon-delivered local anesthetic (LA) techniques such as wound infiltration and regional nerve blocks can play a significant role in the improvement of postoperative pain relief. Epidural analgesia is no longer considered the "gold standard." Infiltrative techniques with or without catheters are useful for almost all types of surgery.\[[@ref1]\] Although LAs are excellent methods of immediate postoperative pain relief due to concerns of surgical site infection (SSI), wound healing, reluctance of surgeons, lack of knowledge about its effectiveness limits the use of local anesthesia for postoperative pain relief.

We conducted a questionnaire-based observational study of surgeons attitude toward LA use for post operative pain relief. The paper questionnaire was administered to surgical delegates attending two general surgery conferences, one obstetric and one orthopedic conference at different locations. Questions were asked on drugs used for local infiltration, methods of infiltration, surgeons knowledge of duration of action of LAs, whether LAs cause infection use of long-acting LAs and surgeons attitude toward whether LA infiltration reduces postoperative analgesic requirements.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

The Institutional Ethical Committee approval was obtained for the survey. A 15-point questionnaire \[[Appendix 1](#App1){ref-type="app"}\] was designed covering the usual areas of general surgical, obstetric, and orthopedic practice. These paper questionnaires were administered to surgical delegates attending two general surgery conferences, one obstetric and one orthopedic conference (either state or interstate level) at different cities in South India. The questionnaire used is shown in Appendix 1. Respondents were instructed to indicate the most common scenario in their practice for each question. Multiple responses for the same question were considered invalid and unfilled as nonresponses. Statistical analysis was done using STATA version 12.0 (Stata Corp LP, Texas, USA). Individual question analysis was performed with Chi-square goodness of fit with CSGOF download in STATA. Question and grade comparisons were performed with the Chi-square test and Fisher\'s exact test where appropriate. Results were reported as percentages and confidence interval for proportions with *P* \< 0.05 as statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 571 questionnaires were returned out of distributed 875 giving a response rate of 65.26%. Multiple responses for the same question were considered invalid and unattempted as nonresponses.

Distribution of categories of respondents {#sec2-1}
-----------------------------------------

[Figure 1](#F1){ref-type="fig"} shows the distribution of three categories of surgeons. Hospital consultants comprised 38% surgical residents 36% and independent surgeons not employed by other comprised 24%.

![Distribution of categories of respondents](AER-13-452-g001){#F1}

All surgeons opinion on the use of LA for post operative pain relief {#sec2-2}
--------------------------------------------------------------------

[Table 1](#T1){ref-type="table"} lists the characteristics of combined responses of all categories of surgeons. Thirty-one percent of surgeons used LA regularly, 31% occasionally, and 35% never used LA for postoperative analgesia. 50% of all surgeons used lignocaine for LA (*P* \< 0.0001), 19% used bupivacaine and 28% combination of lignocaine and bupivacaine, and only 2% other drugs. 65% used infiltration method only (*P* \< 0.0001 vs. other methods), \<2% used LA catheters, and \< 3.6% used preincisional LA. For laparoscopic surgeries, 24% used peritrocal LA, 4.5% used intraperitoneal, and 9.8% used combination (*P* \< 0.0001). 50% responders opined that there is no need to use LA for pain relief when regional anesthesia is used as technique of anesthesia. There was statistically significant difference in responders opinion for duration of action of bupivacaine infiltration (48% 2--4 h, 16% 2--4 h, and 30% 4--8 h, *P* = 0.0001). 68% surgeons opined that time to first analgesic dose and 64% responders said total analgesic dose in the 1^st^ postoperative day is significantly prolonged (*P* \< 0.0001). 23% of all surgeons opined that LA use increases SSI. 60% surgeons were of the view that LA infiltration will not any effect on the incidence of SSI (*P* \< 0.0001). 53% surgeons opined that LA drugs have no effect on microbes, 7% responders said LA drugs support microbial growth. 4% surgeons said that local anesthesia drugs *per se* are antimicrobial (*P* \< 0.0001). 43% opined multiuse vials are the cause of SSI (*P* \< 0.0001). Less than 5% responders used long-acting liposomal bupivacaine, 53% were willing to use liposomal bupivacaine if available, and 41% would use liposomal bupivacaine only after further research evidence on risks and benefits. Overall, 70% surgeons opined that LA infiltration is useful without risk of infection (*P* \< 0.0001), but 23% opined that LA infiltration carries risks of SSI.

###### 

All surgeons opinion on the use of local anesthetics - total 571

  Characteristic                                        *n* (%)       95% CI        *P*
  ----------------------------------------------------- ------------- ------------- -------------------------------
  Frequency of using LA                                                             
   Regularly                                            186 (32.57)   28.85-36.52   0.409
   Occasionally                                         180 (31.52)   27.84-35.44   
   Never                                                205 (35.90)   32.07-39.92   
  Drug used for infiltration                                                        
   Lignocaine                                           286 (50.08)   46.00-54.18   \<0.0001
   Sensorcaine (bupivacaine)                            111 (19.44)   16.40-22.89   
   Combination of lignocaine + sensorcaine              162 (28.37)   24.83-32.20   
   Other                                                12 (2.10)     1.21-3.64     
  Methods of LA use                                                                 
   Infiltration only                                    376 (65.85)   61.87-69.62   \<0.0001
   LA catheter                                          9 (1.58)      0.83-2.97     
   Preincision                                          21 (3.68)     2.42-5.56     
   Tumescent for liposuction                            4 (0.70)      0.27-1.79     
   All                                                  20 (3.50)     2.28-5.34     
   Infiltration and preincision                         54 (9.46)     7.32-12.14    
   Infiltration + LA catheter                           21 (3.68)     2.42-5.56     
   Infiltration, preincision, catheter                  58 (10.16)    7.94-12.91    
   Infiltration, preincision, tumescent                 4 (0.7)       0.27-1.79     
   Infiltration, catheter, tumescent                    3 (0.53)      0.18-1.54     
   Catheter, preincision, tumescent                     1 (0.18)      0.03-0.99     
  Methods of LA for laparoscopy                                                     
   Peritrocal                                           135 (23.64)   20.34-27.29   \<0.0001
   Intraperitoneal                                      26 (4.55)     3.53-7.63     
   Combined                                             56 (9.81)     7.63-12.52    
   None                                                 163 (28.55)   25.00-32.39   
  No need of LA supplement in regional anesthesia                                   
   Yes                                                  284 (49.74)   45.63-53.83   0.9012
   No                                                   287 (50.26)   46.17-54.35   
  Duration of bupivacaine action (h)                                                \<0.0001
   0-2                                                  91 (15.94)    13.17-19.17   
   2-4                                                  275 (48.16)   44.09-52.26   0.0002 for 2-4 h versus 4-8 h
   4-8                                                  174 (30.47)   26.84-34.37   
   8-12                                                 24 (4.2)      2.84-6.17     
  Time to first analgesic dose                                                      
   Significantly prolonged                              389 (68.13)   64.20-71.82   \<0.0001
   Not significantly                                    142 (25.05)   21.49-28.86   
   Not at all                                           40 (5.77)     3.97-8.04     
  Total analgesic dose in the 1^st^ postoperative day                               
   Significantly reduced                                351 (63.95)   59.78-67.96   \<0.0001
   Not significantly                                    147 (24.87)   21.50-28.58   
   Not at all                                           58 (10.16)    7.94-12.81    
  Common LA drugs                                                                   
   Support microbial growth                             45 (7.88)     5.34-10.38    \<0.0001
   Are antimicrobial                                    19 (3.33)     2.14-5.14     
   Have no effect on microbes                           305 (53.42)   48.32-57.47   
   Don't know                                           192 (33.63)   29.88-37.60   
  SSI with LA use for incisional closure                                            
   Increase                                             132 (23.12)   19.85-26.75   \<0.0001
   Decrease                                             21 (3.68)     2.42-5.56     
   No effect                                            318 (59.69)   51.59-59.71   
   Don't know                                           80 (14.01)    11.4-17.1     
  Cause of SSI                                                                      
   LA drug                                              45 (7.88)     5.94-10.38    \<0.001
   Multiuse vials                                       243 (42.56)   38.57-48.65   
   Surgical site                                        77 (13.49)    10.93-16.54   
   Don't know                                           132 (23.12)   19.77-26.84   
   Vial and surgical site                               59 (10.33)    8.09-13.10    
   Drug and vials                                       10 (1.75)     0.95-3.19     
   Drug and surgical site                               5 (0.88)      0.38-2.04     
  Use of liposomal bupivacaine (DepoFoam^®^/exparel)                                
   Yes                                                  26 (4.55)     3.12-6.58     \<0.0001
   No                                                                               
   Will consider if available                           308 (53.94)   49.84-57.99   
   Will consider with more evidence                     234 (40.98)   37.02-45.06   
  Overall impression with LA use                                                    
   Definitely helpful no risk                           400 (70.05)   66.17-73.66   \<0.0001
   Definitely not helpful                               29 (5.08)     3.56-07.20    
   Helpful but infection risk                           142 (24.87)   21.50-28.58   

SSI=Surgical site infection, LA=Local anesthetic

Group opinion -General surgeons, orthopedic surgeons and gynecologists {#sec2-3}
----------------------------------------------------------------------

Table [2](#T2){ref-type="table"}--[4](#T4){ref-type="table"} list the characteristics of responses from general surgeons, orthopedic surgeons, and gynecologists. Forty-one percent of general surgeons, 17% orthopedic surgeons, and 37% gynecologists used LA regularly. 24% of general surgeons, 53% orthopedic surgeons, and 32% gynecologists never used LA. These differences were statistically significant for general surgeons (*P* = 0.003) and orthopedic surgeons (*P* = 0.0001) but not for gynecologists. Infiltration was the most common method among all types of surgeons (69%, 57%, and 71%, respectively). Lignocaine was the most common drug among general surgeons (46%) and gynecologists (73%), while orthopedic surgeons (53%) opted for combination of lignocaine and bupivacaine. These differences were statistically significant within the respective group of surgeons (*P* \< 0.000l, respectively). More than 33-36% of general surgeons and gynecologists used peritrocal, while only 7% used intraperitoneal instillation during laparoscopy (*P* \< 0.0001). While majority of general surgeons (61%) and gynecologists (64%) opined that there is no need to use LA s for postoperative pain, 75% orthopedic surgeons opined LA can be used for postoperative pain even with regional anesthesia intraoperatively. Statistically, these were more significant (orthopedic surgeons *P* \< 0.0001 and other two groups, *P* = 0.001). For duration of action of bupivacaine, 47% general surgeons, 55% orthopedic surgeons, and 45% gynecologists opined as 2--4 h. Only 26% of general surgeons and gynecologists and 38% orthopedic surgeons said that the duration of bupivacaine infiltration is 4--8 h (*P* \< 0.0001). 61% general surgeons, 58% gynecologists, and 83 orthopedic surgeons agreed that time to rescue analgesia is significantly prolonged by LA use. 50% general surgeons, 55% gynecologists, and 80% orthopedic surgeons opined that the total analgesic dose on the 1^st^ postoperative day is significantly reduced with LA use (*P* \< 0.0001).

###### 

General surgeons opinion on the use of local anesthetics-total 241

  Characteristic                                        *n* (%)       95% CI          *P*
  ----------------------------------------------------- ------------- --------------- --------------------------
  Frequency of using LA                                                               0.003
   Regularly                                            101 (41.91)   35.86-48.22     
   Occasionally                                         82 (34.02)    28.33-40.21     *r*
   Never                                                58 (24.07)    19.11-29.85     
  Drug used for infiltration                                                          \<0.0001
   Lignocaine                                           111 (46.06)   39.88-52.37     
   Sensorcaine (bupivacaine)                            74 (30.71)    25.23-36.80     
   Combination of lignocaine+ sensorcaine               47 (19.50)    14.99-24.96     0.0017 versus lignocaine
   Other                                                9 (3.73)      01.97-6.94      
  Methods of LA use                                                                   
   Infiltration only                                    167 (69.29)   63.20-74.77     \<0.0001
   LA Catheter                                          4 ( 1.66)     00.65-4.19      
   Preincision                                          4 ( 1.66)     00.65-4.19      
   Tumescent for liposuction                            4 ( 1.66)     00.65-4.19      
   All                                                  10 (4.15)     2.27-7.47       
   Infiltration and preincision                         34 (14.11)    10.28-19.07     
   Infiltration + LA ctheter                            5 (2.07)      00.89-4.76      
   Infiltration, preincision, catheter                  5 (2.07)      00.89-4.76      
   Infiltration, preincision, tumescent                 4 (1.66)      00.65-4.19      
   Infiltration, catheter, tumescent                    3 (1.24)      00.42-3.59      
   Catheter, preincision, tumescent                     1 ( 0.41)     00.07-2.30      
  Methods of LA for laparoscopy                                                       
   Peritrocal                                           88 (36.51)    30.69-42.76     \<0.0001
   Intraperitoneal                                      16 (6.64)     4.13-10.51      
   Combined                                             28 (11.62)    08.16-16.28     
   None                                                 109 (45.23)   39.07---51.54   
  No need of LA supplement in regional anesthesia                                     
   Yes                                                  147 (61.00)   54.72-66.94     0.001
   No                                                   94 (39.00)    33.06-45.28     
  Duration of bupivacaine action (h)                                                  
   0-2                                                  44 (18.26)    13.89-23.62     \<0.0001
   2-4                                                  107 (47.62)   38.26-50.71     
   4-8                                                  64 (26.56)    21.38-32.47     
   8-12                                                 23 (9.54)     6.44-13.91      
  Time to first analgesic dose                                                        
   Significantly prolonged                              148 (61.41)   55.13-67.33     \<0.0001
   Not significantly                                    78 (32.37)    26.78-38.51     
   Not at all                                           15 (6.22)     3.80-10.01      
  Total analgesic dose in the 1^st^ postoperative day                                 
   Significantly reduced                                122 (50.62)   44.35-56.87     \<0.0001
   Not significantly                                    86 (35.68)    29.90-41.91     
   Not at all                                           25 (10.37)    7.12-14.86      
  Common LA drugs                                                                     
   Support microbial growth                             23 (9.54)     6.44-13.91      \<0.0001
   Are antimicrobial                                    9 (3.73)      1.97-6.94       
   Have no effect on microbes                           154 (63.90)   57.66-69.70     
   Don't know                                           55 (22.82)    17.97-28.52     
  SSI with LA use for incisional closure                                              
   Increase                                             44 (18.26)    13.89-23.62     \<0.0001
   Decrease                                             14 (5.81)     3.49-9.51       
   No effect                                            144 (59.75)   53.45-65.74     
   Don't know                                           30 (12.45)    8.86-17.22      
  Cause of SSI                                                                        
   LA drug                                              15 (6.22)     3.80-10.01      \<0.0001
   Multiuse vials                                       102 (42.32)   36.25-48.63     
   Surgical site                                        44 (18.26)    13.89-23.62     
   Don't know                                           53 (21.99)    17.22-27.64     
   Vial and surgical site                               21 (8.71)     5.77-12.95      
   Drug and vial                                        6 (2.49)      1.15-05.32      
  Use of liposomal bupivacaine (DepoFoam^®^/exparel)                                  
   Yes                                                  17 (7.05)     04.45-11.00     \<0.0001
   No will consider if available                        164 (68.05)   61.92-73.61     
   Will consider with more evidence                     58 (24.07)    19.11-29.85     
  Overall impression with LA use                                                      
   Definitely helpful no risk                           184 (76.35)   70.6-81.28      \<0.0001
   Definitely not helpful                               13 (05.39)    3.18-9.00       
   Helpful but infection risk                           44 (18.26)    13.89-23.62     

CI=Confidence interval, LA=Local anesthetic

###### 

Orthopedic surgeons opinion on the use of local anesthetics-total 191

  Characteristic                                        *n* (%)       95% CI         *P*
  ----------------------------------------------------- ------------- -------------- ----------
  Frequency of using LA                                                              
   Regularly                                            33 (17.28)    12.58-23.27    \<0.0001
   Occasionally                                         56 (29.32)    23.32-36.13    
   Never                                                102 (53.40)   46.33-60.34    
  Drug used for infiltration                                                         
   Lignocaine                                           73 (38.22)    31.63-45.28    \<0.0001
   Sensorcaine (bupivacaine)                            13 (6.81)     04.02-11.30    
   Combination of lignocaine + sensorcaine              102 (53.4)    46.33-60.34    
   Other                                                3 (01.57)     00.54-4.51     
  Methods of LA use                                                                  
   Infiltration only                                    109 (57.07)   49.98-63.88    \<0.0001
   LA Catheter                                          3 (1.57)      00.54-4.51     
   Preincision                                          7 (3.66)      1.78-7.36      
   All                                                  5 (2.62)      1.12-05.98     
   Infiltration and preincision                         11 (5.76)     3.25-10.02     
   Infiltration + LA ctheter                            3 (1.57)      00.54-4.51     
   Infiltration, preincision, catheter                  53 (27.75)    21.89-34.49    
  No need of LA supplement in regional anesthesia                                    
   Yes                                                  47 (24.61)    19.04-31.18    \<0.0001
   No                                                   144 (75.39)   68.82-80.96    
  Duration of bupivacaine action (h)                                                 \<0.0001
   0-2                                                  10 (5.24)     2.87-09.37     0.0028
   2-4                                                  105 (54.97)   47.89-61.86    0.0328
   4-8                                                  74 (38.74)    32.12-45.81    0.0379
   8-12                                                 \-            \-             \-
  Time to first analgesic dose                                                       
   Significantly prolonged                              160 (83.77)   77.88-88.32    \<0.0001
   Not significantly                                    19 (9.95)     6.46-15.02     
   Not at al                                            12 (6.28)     3.63-10.66     
  Total analgesic dose in the 1^st^ postoperative day                                
   Significantly reduced                                152 (79.58)   73.31-84.69    \<0.0001
   Not significantly                                    18 (9.48)     6.04-14.40     
   Not at all                                           17 (8.90)     5.63-13.79     
  Common LA drugs                                                                    
   Support microbial growth                             19 (9.95)     6.46-15.02     \<0.0001
   Are antimicrobial                                    4 (2.09)      00.81-5.25     
   Have no effect on microbes                           72 (37.7)     31.13-44.75    
   Don't know                                           96 (50.26)    43.23-57.28    
  SSI with LA use for incisional closure                                             
   Increase                                             72 (37.70)    31.13-44.75    
   Decrease                                             4 (2.09)      00.81-5.25     \<0.0001
   No effect                                            86 (45.03)    38.14-52.11    
   Don't know                                           24 (12.57)    8.59-18.02     
  Cause of SSI                                                                       
   LA drug                                              25 (13.09)    9.03-18.61     \<0.0001
   Multi use vials                                      81 (42.41)    35.62-49.50    
   Surgical site                                        16 (8.38)     5.22-13.18     
   Don't know                                           41 (21.47)    16.24-27.83    
   Vial and surgical site                               22 (11.52)    7.73\--16.83   
   Drug + vial                                          2 (1.05)      00.29-03.74    
   Drug + surgical site                                 4 (02.09)     00.81-5.25     
  Use of liposomal bupivacaine (DepoFoam^®^/exparel)                                 
   Yes                                                  6 (3.14)      1.45-06.68     \<0.0001
   No will consider if available                        58 (30.37)    24.29-37.23    
   Will consider with more evidence                     127 (66.49)   59.53-72.80    
  Overall impression with LA use                                                     
   Definitely helpful no risk                           125 (65.45)   58.46-71.83    \<0.0001
   Definitely not helpful                               8 (4.19)      2.14-8.05      
   Helpful but infection risk                           58 (30.37)    24.29-37.23    

CI=Confidence interval, LA=Local anesthetic

###### 

Gynecologists opinion on the use of local anesthetics-total 139

  Characteristic                                        *n* (%)       95% CI        *P*
  ----------------------------------------------------- ------------- ------------- ----------
  Frequency of using LA                                                             
   Regularly                                            52 (37.41)    29.81-45.69   0.56
   Occasionally                                         42 (30.22)    23.20-38.30   
   Never                                                45 (32.37)    25.16-40.53   
  Drug used for infiltration                                                        
   Lignocaine                                           102 (73.38)   65.48-80.03   \<0.0001
   Sensorcaine (bupivacaine)                            24 (17.27)    11.89-24.41   
   Combination of lignocaine + sensorcaine              13 (09.35)    05.55-15.34   
   Other                                                                            
  Methods of LA Use                                                                 
   Infiltration only                                    100 (71.94)   63.96-78.74   \<0.0001
   LA catheter                                          2 (01.44)     00.40-05.51   
   Preincision                                          10 (07.19)    03.95-12.73   
   All                                                  5 (03.60)     01.55-08.15   
   Infiltration and preincision                         9 (06.47)     03.44-11.84   
   Infiltration + LA catheter                           13 (09.35)    05.55-15.34   
  Methods of LA for laparoscopy                                                     
   Peritrocal                                           47 (33.81)    26.48-42.02   \<0.0001
   Intraperitoneal                                      10 (07.19)    03.95-12.73   
   Combined                                             28 (20.14     14.32-27.57   
   None                                                 54 (38.85)    31.15-47.15   
  No need of LA supplement in regional anesthesia                                   
   Yes                                                  90 (64.75)    56.51-72.20   
   No                                                   49 (35.25)    27.80-43.49   0.001
  Duration of bupivacaine action (h)                                                
   0-2                                                  37 (26.62)    19.97-34.52   \<0.0001
   2-4                                                  63 (45.32)    37.28-53.61   
   4-8                                                  36 (25.90)    19.33-33.76   
   8-12                                                 1 (00.72)     00.13-03.96   
  Time to first analgesic dose                                                      
   Significantly prolonged                              81 (58.27)    49.96-66.14   \<0.0001
   Not significantly                                    45 (32.37)    25.16-40.53   
   Not at all                                           13 (09.35)    05.55-15.34   
  Total analgesic dose in the 1^st^ postoperative day                               
   Significantly reduced                                77 (55.40)    47.10-63.41   \<0.0001
   Not significantly                                    43 (30.94)    23.85-39.05   
   Not at all                                           16 (11.51)    07.21-17.88   
  Common LA drugs                                                                   
   Support microbial growth                             3 (02.16)     00.74-06.16   \<0.0001
   Are antimicrobial                                    6 (04.32)     02.00-9.10    
   Have no effect on microbes                           79 (56.83)    54.11-71.64   
   Don't know                                           41 (29.50)    22.55-37.55   
  SSI with LA use for incision closure                                              
   Increase                                             16 (11.51)    07.21-17.88   \<0.0001
   Decrease                                             3 (02.16)     00.74-06.16   
   No effect                                            88 (63.31)    55.04-70.86   
   Don't know                                           26 (18.71)    13.10-26.00   
  Cause of SSI                                                                      
   LA drug                                              5 (3.6)       01.55-04.44   \<0.0001
   Multiuse vials                                       60 (43.17)    35.23-51.48   
   Surgical site                                        17 (12.23)    07.78-18.71   
   Don't know                                           38 (27.34)    20.61-35.28   
   Vial and surgical site                               16 (11.51)    07.21-17.88   
   Drug and vial                                        2 (01.44)     00.40-05.10   
   Drug and surgical site                               1 (0.72)      00.13-03.96   
  Use of liposomal bupivacaine (DepoFoam^®^/exparel)                                
   Yes                                                  3 (02.16)     00.74-06.16   \<0.0001
   Will consider if available                           86 (61.87)    53.58-69.52   
   Will consider with more evidence                     49 (35.25)    27.80-43.49   
  Overall impression with LA use                                                    
   Definitely helpful no risk                           91 (65.47)    57.25-72.86   \<0.0001
   Definitely not helpful                               8 (05.76)     02.95-10.95   
   Helpful but infection risk                           40 (28.78)    21.90-36.80   

SSI=Surgical site infection, CI=Confidence interval, LA=Local anesthetic

About 3.8% general surgeons, 4.3% gynecologists, and 2% of orthopedic surgeons said that LA drugs are antimicrobial. 18% general surgeons, 37% orthopedic surgeons, and 11% gynecology surgeons opined LA use for incisional closure increases SSIs. Among vials, drug itself and surgical site, 42%--43% of all categories of surgeons opined multiuse vials are the cause of SSI (*P* \< 0.0001). Depo LA preparations were used more commonly by general surgeons (7%) than the other two (3%). Sixty-eight percent general surgeons and 61% gynecologists said will consider long-acting liposomal bupivacaine if available, while 66% orthopedic surgeons said will consider liposomal bupivacaine in their practice only after further research evidnce become available. Overall 76% general surgeons and 65% gynecologists and orthopedic surgeons opined that LA infiltration is useful without risks of SSI. About 5% of all surgeons opined LA use is not useful. Overall 18% general surgeons, 30% orthopedic surgeons, and 28% gynecologists opined that LA use for postoperative analgesia is helpful but carries risks of SSI. These differences were statistically significant (*P* \< 0.0001).

Comparison of responses among consultants, residents and practitioners {#sec2-4}
----------------------------------------------------------------------

[Table 5](#T5){ref-type="table"} lists the characteristics of responses among consultants, residents, and independent practitioners. 37% hospital consultant surgeons used LA regularly and 28% residents and 30% independent practitioners used LA regularly (consultant to practitioner odds ratio \[OR\] 1.3641). Lignocaine was the most common drug among all grades (45%, 50%, and 56%, respectively, differences not significant across grades, *P* = 0.111). However, bupivacaine was more commonly used by hospital consultants than practitioners (23% vs. 14%, OR 1.8249). Less than 2% of all grades used LA catheters. For laparoscopic surgeries, peritrocal was more common than intraperitoneal among all grades (45%, 30%, and 26% vs. 6%, 7%, and 5%, *P* = 0.008). Consultants more commonly used peritrocal LA than practitioners (OR 2.0938). 62% practitioner surgeons opined LA can be supplemented with regional anesthesia techniques. 51% consultants, 50% residents, and 42% practitioner surgeons said that the duration of action of bupivacaine infiltration is 2--4 h (consultants, residents and practitioners 30%, 27%, and 36% respectively said 4-8 h). 72% consultants, 71% residents, and 56% practitioners opined that time to the first analgesic is significantly prolonged (*P* = 0.01), but differences for total dose of analgesics was not statistically significant. 8% practitioners said LA drugs are antimicrobial (\<2% consultants and residents). 20% of consultants, 26% residents, and 25% practitioners surgeons said LA use for incision closure use increases risk of SSI. 63% consultants, 55% residents, and 52% independent practitioner surgeons said LA drugs have no effect on microbes. Multiuse vials were cited as the most common cause of SSI (42%, 45%, and 30%, respectively, *P* \< 0.0001). 17% consultants and 18% of practitioner surgeons opined surgical site also contributed to SSI. Only 5% of all grades used long-acting liposomal bupivacaine (*P* = 0.02), and more consultants were willing to use liposomal bupivacaine than practitioners (63% vs. 47%, OR 1.9151. There were no statistical differences across grades for the overall impression of LA use.

###### 

Comparison of responses among consultants, residents, and practitioners

  Characteristic                                        *n* (%), 95% CI            *P*                       OR (95% CI and, *P*) for consultant/practitioner                                     
  ----------------------------------------------------- -------------------------- ------------------------- -------------------------------------------------- --------------------------------- ----------------------------------
  Frequency of using LA                                                                                                                                                                           
   Regularly                                            82 (37.44) 31.30-44.01     61 (28.91) 23.21-35.36    43 (30.50) 23.50-38.53                             0.175                             1.3641 (0.8689-2.1416, 0.1772)
   Occasionally                                         67 (30.59) 24.87-36.98     63 (29.86) 24.09-36.35    50 (35.46) 28.05-43.65                             0.8022 (0.5120-1.2570, 0.3362)    
   Never                                                70 (31.96) 26.14-38.40     87 (41.23) 34.80-47.97    48 (34.04) 26.73-42.19                             0.9102 (0.5807-1.4267, 0.6817)    
  Drug used for infiltration                                                                                                                                                                      
   Lignocaine                                           98 (45.16) 38.68-51.81     104 (50.73) 43.94-57.50   84 (56.38) 48.36-64.08                             0.111                             0.6373 (0.4187-0.9698, 0.0354)
   Sensorcaine (bupivacaine)                            50 (23.04) 17.94-29.08     40 (19.51) 14.67-25.47    21 (14.09) 09.40-20.58                             1.8249 (1.0432-3.1925, 0.0350)    
   Combination of lignocaine + sensorcaine              61 (28.11) 22.55-34.43     58 (28.29) 22.85-34.81    43 (28.86) 22.19-36.59                             0.9639 (0.6075-1.5296, 0.8761)    
   Other                                                8 (03.69) 01.88-07.11      3 (01.46) 0.50-04.21      1 (00.67) 00.12-03.70                              5.6651 (0.7010-45.7801, 0.1038)   
  Methods of LA use                                                                                                                                                                               
   Infiltration only                                    146 (65.77) 59.31-71.70    135 (62.79) 56.16-68.97   95 (70.09) 62.71-77.92                             0.345                             0.7886 (0.4956-1.2550, 0.3164)
   LA Catheter                                          4 (1.80) 00.70-04.54       3 (1.40) 00.48-04.03      2 (1.49) 00.41-05.27                               1.2110 (0.2188-6.7031, 0.8264)    
   Preincision                                          9 (4.05) 02.14-07.52       10 (4.65) 02.54-08.35     2 (1.49) 00.41-05.27                               2.8019 (0.5962-13.1685, 0.1919)   
   Tumescent for liposuction                            2 (0.90) 00.25-03.22       1 (0.47) 00.08-02.60      1 (0.75) 00.13-04.11                               1.2091 (0.1086-13.4638, 0.8773)   
   All                                                  10 (4.50) 02.46-08.09      8 (3.72) 01.90-07.17      2 (1.49) 00.41-05.27                               3.1132 (0.6716-14.4304, 0.1467)   
   Infiltration and preincision                         17 (07.66) 04.84---11.92   21 (09.77) 06.48-14.47    16 (11.94) 07.48-18.52                             0.6116 (0.2979-1.2556, 0.1803)    
   Infiltration + LA catheter                           6 (02.70) 01.24-05.77      6 (2.79) 1.28-5.95        9 (06.72) 03.58-12.28                              0.3858 (0.1342-1.1094, 0.0772)    
   Infiltration, preincision, catheter                  26 (11.71) 08.12-16.61     26 (12.09) 08.39-17.13    6 (04.48) 02.07-09.43                              2.8299 (1.1332-7.0673, 0.0259)    
   Infiltration, preincision, tumescent                 2 (0.90) 00.25-03.22       1 (0.47) 00.08-02.60      1 (00.75) 00.13-04.11                              1.2091 (0.1086-13.4638, 0.8773)   
   Infiltration, catheter, , tumescent                  0 (0.00)                   3 (0.47) 00.48-4.03       0 (0.00)                                           \-                                
   Catheter, preincision, tumescent                     0 (0.00)                   1 (0.47) 00.08-02.60      0 (0.00)                                           \-                                
  Methods of LA for laparoscopy                                                                                                                                                                   
   Peritrocal                                           67 (45.27) 37.47-53.31     36 (30.23) 22.72-39.01    32 (26.89) 19.74-35.49                             0.008                             2.0938 (1.2426-3.5280, 0.0055)
   Intraperitoneal                                      10 (06.76) 03.71-11.99     9 (07.56) 04.03-13.76     7 (05.88) 02.88-11.64                              1.0973 (0.4043-2.9784, 0.8554)    
   Combined                                             25 (16.89) 11.71-23.75     19 (15.97) 10.47-23.60    12 (10.08) 05.86-16.80                             1.7107 (0.8187-3.5745, 0.1533)    
   None                                                 46 (31.08) 24.18-39.94     55 (46.22) 37.52-55.16    62 (52.1) 43.20-60.87                              0.3710 (0.2231-0.6168, 0.00)      
  No need of LA supplement in regional anesthesia                                                                                                                                                 
   Yes                                                  125 (57.08) 50.46-63.46    107 (50.23) 43.57-56.88   52 (37.41) 29.81-45.69                             0.001                             2.2248 (1.4394-3.4389, 0.0003)
   No                                                   94 (42.92) 36.54-49.54     106 (49.77) 43.12-56.43   87 (62.59) 54.31-70.19                                                               0.4495 (0.2908-0.6947, 0.0003)
  Duration of bupivacaine action (h)                                                                                                                                                              
   0-2                                                  30 (13.76) 09.81-18.96     41 (19.34) 14.59-25.18    20 (14.93) 09.88-21.94                             0.258                             0.9096 (0.4933-1.6770, 0.7614)
   2-4                                                  112 (51.38) 44.78-57.93    106 (50.00) 44.33-56.67   57 (42.54) 34.49-51.00                             1.4273 (0.9254-2.2016, 0.1076)    
   4-8                                                  66 (30.28) 24.57-36.68     59 (27.83) 22.23-34.22    49 (36.57) 28.90-44.99                             0.7532 (0.4779-1.1873, 0.2222)    
   8-12                                                 10 (4.59) 02.51-08.24      6 (2.83) 01.30-06.40      8 (05.97) 03.06-11.34                              0.7572 (0.2912-1.9691, 0.5684)    
  Time-first analgesic dose                                                                                                                                                                       
   Significantly prolonged                              154 (72.64) 66.28-78.20    153 (71.83) 65.44-77.44   82 (56.16) 48.06-63.95                             0.01                              2.0723 (1.3280-3.2340, 0.0013)
   Not significantly                                    46 (21.70) 16.68-27.73     46 (21.60) 16.60-27.60    50 (34.25) 27.04-42.26                             0.5320 (0.3316-0.8536l, 0.0089)   
   Not at all                                           12 (05.66) 03.27-09.63     14 (06.57) 03.95-10.73    14 (09.59) 05.80-15.45                             0.5657 (0.2537-1.2613, 0.1637)    
  Total analgesic dose in the 1^st^ postoperative day                                                                                                                                             
   Significantly reduced                                141 (66.82) 60.22-72.82    133 (64.88) 58.13-71.09   77 (55.00) 46.74-63.00                             0.184                             1.6481 (1.0621-2.5572, 0.0258)
   Not significantly                                    52 (24.64) 19.31-30.87     49 (23.90) 19.00-30.99    46 (32.86) 25.63-41.01                             0.6683 (0.4170-1.0710, 0.0940)    
   Not at all                                           18 (08.53) 05.46-13.08     23 (11.22) 07.59-16.27    17 (12.14) 07.72-18.58                             0.6748 (0.3350-1.3594, 0.2710)    
  Common LA drugs                                                                                                                                                                                 
   Support microbial growth                             16 (07.62) 04.74-12.02     13 (6.28) 03.71-10.45     16 (11.11) 06.96-17.29                             0.004                             0.6598 (0.2946-1.2610, 0.1820)
   Are antimicrobial                                    4 (1.90) 00.74-04.79       4 (1.93) 00.75-4.86       11 (7.64) 4.32-13.16                               0.2348 (0.0732-0.7527, 0.0148)    
   Have no effect on microbes                           128 (60.95) 54.21-67.30    107 (51.69) 44.91-58.40   70 (48.61) 40.59-56.70                             1.6502 (1.0750-2.5331, 0.0220)    
   Don't know                                           62 (29.52) 23.76-36.01     83 (40.10) 33.66-45.30    47 (32.64) 25.52-40.66                             0.8646 (0.5472-1.3661, 0.5330)    
  SSI with LA use for incision closure                                                                                                                                                            
   Increase                                             43 (20.77) 15.80-26.80     55 (26.32) 20.82-32.68    34 (25.19) 18.62-33.13                             0.009                             0.7789 (0.4660-1.3017, 0.3402)
   Decrease                                             5 (2.42) 1.04-05.53        4 (01.91) 00.74-04.81     12 (08.89) 5.16-14.90                              0.2537 (0.0873-0.7375, 0.0118)    
   No effect                                            132 (63.77) 57.03-70.01    115 (55.02) 48.25-61.61   71 (52.59) 44.21-60.82                             1.5865 (1.0208-2.4657, 0.0402)    
   Don't know                                           27 (13.04) 9.12-18.31      35 (16.75) 12.30-22.40    18 (13.33) 8.60-20.09                              0.9750 (0.5140-1.8495, 0.9382)    
  Cause of SSI                                                                                                                                                                                    
   LA drug                                              11 (5.05) 01.97-08.12735   23 (10.40) 06.15-14.64    11 (7.69) 04.35-13.25                              \<0.0001                          0.6640 (0.2781-1.5662, 0.3460)
   multiuse vials                                       96 (42.93) 35.97-49.88     103 (45.54) 38.61-52.47   44 (30.77) 23.79-38.76                                                               1.8783 (1.2016-2.9360, 0.0057)
   surgical site                                        34 (17.17) 11.87-22.47     17 (8.42) 4.55-12.27      26 (18.18) 12.72-25.31                                                               0.0.8644 (0.4930-1.5156, 0.6110)
   Don't know                                           52 (25.76) 19.61-31.90     51 (24.75) 18.75-30.75    29 (20.28) 14.51-27.61                                                               1.2856 (0.7689-2.1495, 0.3380)
   Vial and surgical site                               12 (6.06) 2.70-9.41        19 (9.41) 5.34-13.46      28 (19.58) 13.91-26.84                                                               0.2477 (0.1213-0.5059, 0.0001
   Drug and vials                                       5 (2.53) 00.32-4.72        2 (0.99) 00.38-02.36      3 (2.10) 00.29-4.70                                                                  1.1327 (0.2664-4.8162, 0.8660)
   Drug and surgical site                               1 (0.47) 00.08-2.63        2 (0.92) 00.25-03.30      2 (1.40) 00.38-4.96                                                                  0.3357 (0.0302-3.7377, 0.3747)
                                                        211                        217                       143                                                                                  
  Use of liposomal bupivacaine (DepoFoam ^®^/exparel)                                                                                                                                             
   Yes                                                  9 (4.25) 2.25-7.88         10 (4.41) 2.41-7.92       7 (5.43) 2.66-10.78                                0.02                              0.7727 (0.2806-2.1278, 0.6178)
   No, will consider if available                       134 (63.21) 56.54-69.41    113 (49.78) 43.33-56.23   61 (47.29) 38.88-55.86                             1.9151 (1.2281-2.9864, 0.0042)    
   Will consider with more evidence                     69 (32.55) 26.60-39.12     104 (45.81) 39.45-52.31   61 (47.29) 38.88-55.86                             0.5379 (0.3432-0.8431, 0.0068)    
  Overall impression with LA use                                                                                                                                                                  
   Definitely helpful no risk                           159 (73.95) 67.70-79.36    144 (66.67) 60.14-72.62   97 (69.29) 61.22-76.33                             0.587                             1.2587 (0.7860-2.0156, 0.3383)
   Definitely not helpful                               10 (4.65) 2.54-8.35        12 (5.56) 3.21-9.46       7 (5) 2.44-09.96                                   0.9268 (0.3443-2.4949, 0.8804)    
   Helpful but infection risk                           46 (21.4) 16.45-27.36      60 (27.780) 22.23-34.10   36 (25.71) 19.19-33.53                             0.7863 (0.4770-1.2963, 0.3459)    

Values in brackets-CIs for OR and *P* value for OR. OR=Odds ratio, CI=Confidence interval, LA=Local anesthetic

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Simple surgeon-delivered LA techniques such as wound infiltration, preperitoneal or intraperitoneal administration, and local infiltration analgesia can play a significant role in the improvement of postoperative care. [Table 1](#T1){ref-type="table"} lists the characteristics of all surgeons opinion on use of LA drugs. Only 33% of all surgeons used LAs for postoperative pain. Only 2% of all surgeons indicated for other drugs, but no surgeon enumerated about ropivacaine. This reflects lack of knowledge of recent LA drugs. In a French survey, LA infiltration was included in more than 85% of protocols for postoperative pain relief.\[[@ref2]\] Similarly, only 2% responders used LA catheters in our survey, while 18% used continuous wound infiltration (CWI) in the French Survey. Another reason why LA infusion is not popular may be due to perceived risks of infection and reduced wound healing. Meta-analysis has shown that ropivacaine CWI is effective for postoperative pain management in a wide range of surgical procedures.\[[@ref3]\] However, some studies have demonstrated reduction in interleukin 10 and increase in substance P following continuous instillation of bupivacaine for 24 h. Other markers of inflammation did not differ significantly between the groups.\[[@ref4]\] However, it is not known for infusions \<24 h. Brower and Johnson have demonstrated that adverse effects of LA infiltration suggest that the risk is more with continuous infusions.\[[@ref5]\] However, these risks can be attenuated with lower concentrations of LAs.\[[@ref6]\] Also in another study, LA-induced increases in histological markers did not extend beyond the 3^rd^ day, suggesting that wound infiltration with long-acting LA does not impair the wound healing process in rats.\[[@ref7]\] Thus, the perceived risks of infections and wound healing are not supported by sufficient evidence.

About 48% of all surgeons opined that duration of action of bupivacaine infiltration is 2--4 h only, while in reality, it is 4--8 h.\[[@ref8]\] Only 50% of all surgeons used only lignocaine even though bupivacaine offers longer analgesia period. This shows surgeons lack of knowledge about duration of action of common LA drugs. Only \<4% of all surgeons used preincision LA infiltration. Preincisional LA infiltration has been shown to be more efficacious than postincisional infiltration.\[[@ref9]\] It is postulated that inhibition of peripheral sensitization may have a major role in impeding the development of acute pain and attenuating postoperative pain. It is possible that fear of SSIs or bruising discourages surgeons from the use of preincisional LA. However, preincisional LA has been shown to have no effects on bruising or wound cosmesis.\[[@ref10]\]

For laparoscopic surgeries, only 5% used intraperitoneal and 24% used peritrocal infiltration. Peritoneal instillation was also rarely used by the surgeons in the French survey.\[[@ref2]\] A systematic review has shown statistically significant pain relief with intraperitoneal infiltration and mesosalpinx LA block and lack of evidence for port-site infiltration.\[[@ref11]\] These observations demonstrate that surgeons have high threshold for non-infiltrative routes of LA use for postoperative pain relief and attending anesthesiologists have to convince their surgeons with evidence regarding LA drugs, routes and doses of LA for postoperative pain relief, wall posters in operating rooms depicting available LA drugs routes efficacy, and duration of action of LA drugs will indirectly educate surgeons about use of LA for postoperative pain relief.

While 49% of surgeons all surgeons opined that there is no need to use LA for postoperative pain, an equal proportion of 50% opined LA can be used for postoperative pain even with regional anesthesia intraoperatively. LA infiltration has been used with regional anesthesia, both preincisional and postincisional.\[[@ref12][@ref13]\] There is evidence that LA infiltration in the surgical site that included peritoneal, musculofascial, and subdermal planes provides superior pain relief and reduced opioid consumption for 48 h compared to bilateral transversus abdominis plane blocks after open hysterectomy.\[[@ref14]\] Even though 68% surgeons opined that time to first analgesic dose is significantly prolonged and 63% responders opined total analgesic dose in the 1^st^ postoperative day is significantly reduced, only 33% of surgeons used LA regularly, 31% occasionally, and 36% never used LA for postoperative analgesia. These facts show surgeons do know LA is useful for postoperative analgesia but reluctant to use LA drugs for postoperative pain.

The fact that LA drugs are antimicrobial,\[[@ref15][@ref16]\] are known to only 4% of surgeons. This fact could be the reason for underuse of LA for postoperative analgesia. In fact, LA drugs have been used as a strategy of preventing SSI.\[[@ref17]\] In a study using the American College of Surgeons National Surgical Quality Improvement Program database, the incidence of SSIs in patients given local anesthesia was significantly lower than for that of patients given nonlocal anesthesia (0.8 vs. 1.4%,).\[[@ref17]\] LAs at concentrations used in the clinical setting (e.g., bupivacaine 0.125%--0.75%; lidocaine 1%--3%) inhibit the growth of numerous bacteria and fungi under various conditions.\[[@ref18]\] Furthermore, bupivacaine and lidocaine have been shown to inhibit growth to a significantly greater extent than does ropivacaine.\[[@ref18]\] Thus, whether bupivacaine should be preferred for infiltration and infusion over ropivacaine to reduce SSIs should be assessed by further studies. Correspondingly, over 53% surgeons said LA drugs have no effect on microbes and 23% said LA drugs increased chances of SSI. Significant number of surgeons (42% *P* = 0.001) thought that multiuse vials are source of infection. Single-use vials must be encouraged to LA use for postoperative analgesia, especially in the third-world countries.

Bupivacaine extended-release has been shown to provide a statistically significant reduction in pain through 72-h postoperatively and adequate safety and tolerability.\[[@ref19][@ref20]\] Compared to thoracic epidural, liposomal bupivacaine has been to shown to significantly lower pain scores, decreased postoperative opioid medication, and lower total and direct hospital costs in video-assisted thoracoscopic pulmonary resection.\[[@ref21]\] Only \<5% of all surgeons had used long-acting liposomal bupivacaine and almost 40% more were willing to use the liposomal LA drug only if more research evidence is available to them. Liposomal bupivacaine is not widely available in India, but sizeable proportions of surgeons in our survey seem to be cautious for any new LA for postoperative pain relief.

Among all three categories of surgeons, fewer orthopedic surgeons used LA compared to general surgeons and gynecologists (17% vs. 42 and 37%). However, when used, more than 53% of orthopedic surgeons used lignocaine and bupivacaine combination, while gynecologists and general surgeons preferred lignocaine only. Furthermore, 75% of orthopedic surgeons opined that LA infiltration can be used even with regional anesthesia, more orthopedic surgeons correctly enumerated the duration of action of bupivacaine infiltration (38% vs. 26% for other surgeons). More number of orthopedic surgeons opined that time to first analgesic dose and total analgesic dose in the 1^st^ postoperative day is significantly prolonged (\>80% vs. \<60% for other surgeons). Fewer orthopedic surgeons knew LA drugs are antimicrobial (2% vs. 4% for other surgeons). These indicate probably clustering of cases under regional anesthesia and better knowledge of orthopedic surgeons regarding efficacy of LA drugs but not on the impact of LA drugs on SSIs.

Low use (6%----7%) of intraperitoneal instillation by general and gynecologists reflect reluctance and fear of infection among responders. While majority of general surgeons (61%) and gynecologists (64%) opined that there is no need to use LA for postoperative pain, 75% orthopedic surgeons opined LA can be used for postoperative pain even with regional anesthesia intraoperatively. This again may be attributed to cases under regional anesthesia and better understanding of efficacy of LA drugs by orthopedic surgeons. There is equal concern (42%--43%) among all categories of surgeons that multiuse vials are a source of SSI. Thus, the role of single-use LA vials or ampules cannot be overemphasized. Orthopedic surgeons are less likely to use liposomal depot LA drugs (30% vs 61% for other surgeons vs. 66% for other surgeons). This may probably due to concerns of long-standing SSI and implant infections. Also probably for similar reasons, more orthopedic surgeons expressed concerns of infections (37% vs. \<18% for other surgeons) SSI with LA use for incision closure Overall impression among three categories of surgeons was LA is definitely useful without SSI risks (65%--76%).

Local anesthetic use among the three categories of surgeons {#sec2-5}
-----------------------------------------------------------

Hospital consultants used LA drugs regularly more often than residents and independent practitioners (37% vs. 30%, OR 1.3641) and bupivacaine was the most common drug (23% vs. 14%, OR 1.8249). Reasons probably are good knowledge regarding LA drugs and availability of options. Independent practitioner surgeons more often (56% vs. 45%) used lignocaine than bupivacaine for postoperative analgesia and were less likely to use preincisional LA drugs (1.4% vs. 4.0%) probably due to concerns of immediate postoperative pain control, inadequacy of staff, and SSI in smaller hospitals. Independent practicing surgeons were more likely (62% vs. 42% and 49%) than hospital consultants and residents to use LA drugs even with regional anesthesia. This probably reflects the lack of other multimodal methods and cost-effectiveness of postoperative analgesia in smaller hospitals. More independent practicing surgeons (36% vs. 30% for consultants and 27% residents) correctly cited the duration of bupivacaine action and antimicrobial nature of LA drugs (7.6% vs. \<2% for consultants and residents). These reflect better knowledge of LA drugs among practitioners. However, hospital consultants opined LA drugs significantly prolonged time to first analgesic dose (72% vs. 56%, *P* = 0.01) emphasizing knowledge of efficacy of LA among consultants. More consultants and residents opined multiuse vials are source of SSI (45% and 42% vs 30% for practitioners, *P* \< 0.0001). Surgical consultants and residents thus know how a multiuse vial is treated in the operation theater. Consultants are more likely to use liposomal LA drugs if available (63% vs. 47%, OR 1.9151) highlighting the need for long-acting and cost-effective analgesic method.

Limitations {#sec2-6}
-----------

This is a cross-sectional survey, and we asked for the most common scenario rather than percentages in the questions to make the questions as simple and straightforward as possible and to obtain a reasonable number of responses. For example, we asked for the most common drug or method of LA use rather than asking percentage. However, the most common scenario may more correctly estimate the actual scenario for each characteristic. There is also the possibility of overlapping of respondents across the same and different grades from the same hospital. Nevertheless, this survey provides an insight into the surgeons attitudes to LA drug use for postoperative pain relief and develop the methods to promote and encourage LA use for postoperative pain relief.

C[ONCLUSIONS]{.smallcaps} {#sec1-5}
=========================

Although the majority of surgeons were aware of the benefits of LA use for postoperative pain relief, reluctance, lack of knowledge of LA drugs and methods of LA use and fear of infection and wound healing are barriers for effective use of LA drugs for postoperative pain relief. The perceived risks of infections and wound healing are not supported by sufficient evidence. Attending anesthesiologists must develop methods in the operating room to create awareness and convince surgeons with evidence about the effectiveness of LA use for postoperative pain relief. Single-use vials must be encouraged to LA use for postoperative analgesia, especially in the third-world countries. Anesthetic departments must make conscious efforts to educate surgeons both in the operation theater and other settings in the hospital and create awareness among surgeons about the local anesthesia drugs as a central role to postoperative pain relief modalities. Regular audits and interdepartmental presentations must be encouraged as part of education.
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Survey of surgeons attitudes to local anesthetics use for postoperative pain relief

Dear Colleague, This is a questionnaire regarding your practice for use of local anesthetics for postoperative pain relief.
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What grade are you Sir/Madam?□ Teaching faculty/Consultant □ Own Hospital/Practice without attachment□ Postgraduate studentHow often you use local anesthetics infiltration for pain relief□ Regularly (1 in 1--3 cases) □ Occasionally (\>1 in 4) □ NeverWhat do you use for local infiltration?□ Lignocaine □ Sensorcaine (Bupivacaine) □ Combination of Lig + SenOther □ \_\_\_\_\_\_\_\_\_\_\_(specify)What methods of local anesthesia you use? (tick more than one for this question only)□ Infiltration only □ LA catheter □ Preincision□ Tumescent for liposuction □ AllFor laparoscopic surgeries, what methods do you use ?□ Peritrocal □ Intraperitoneal □ Combined □ NoneIf patient has received regional anesthesia, do you think there is no need to infiltrate the incision?□ Yes □ NoHow long does pain relief with bupivacaine (sensorcaine) infiltration last?□ 0--2 h □ 2--4 h □ 4--8 h *P* 8--12 hDo you think Local anesthetic prolongs the *time to first analgesic dose* in the immediate postoperative?□ Significantly □ Not Significantly □ Not at allDo you think Local anesthetic reduces the *total analgesic dose* in the first postoperative day?□ Significantly □ Not Significantly □ Not at allCommonly used Local anesthetics□ Support microbial growth □ Are antimicrobial □ Have no effect on microbes □ Don't knowDoes LA infiltration for incision closure increase surgical site infection?□ Increase □ Decrease □ No effect □ Don't KnowWhat is the cause of infection concerns with local anesthetic infiltration?□ LA Drug □ Multi use vials □ Surgical site □ Don't knowHave you used long acting (72--96 h) liposomal bupivacaine (DepoFoam^®^/Exparel^®^) local infiltration for pain relief?□ Yes, No of Times \_\_\_\_\_\_Side effect\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_□ No but will consider if available□ Will consider subject to more reports/trial outcomes on infections/complicationsYour overall impression with local anesthetic use for pain reliefπ Definitely helpful no risk π Definitely not helpful π Helpful but infection riskAny comments

            Thank you for your participation
